paclitaxel protein-bound particles (albumin-bound)

Step 1: Nab-paclitaxel is injected into the blood vessels.
Step 2: Nab-paclitaxel dissociates into individual particles while suspended in the blood.
Step 3: The albumin-associated nab-paclitaxel binds to gp60 receptors found on the endothelial cells of tumor blood vessels.
Step 4: The binding of albumin to gp60 facilitates the delivery of nab-paclitaxel to the tumor site.

Paclitaxel is formulated in a solvent mixture of polyoxyethylated castor oil and dehydrated alcohol, while nab-paclitaxel is a solvent-free albumin-bound nanoparticle formulation of paclitaxel.

Another application of EPR-based nanovectors for breast cancer is the use of albumin-bound (nab-)paclitaxel ABI-007 (Abraxane®; Abraxis BioScience and AstraZeneca).

Albumin has the ability to bind to both endogenous ligands, like fatty acids, and exogenous ligands, such as warfarin, penicillin, and diazepam. This reversible binding allows albumin to act as a drug reservoir, enhancing the distribution and availability of these drugs in the body.

nab-Paclitaxel takes advantage of albumin’s natural properties to bind paclitaxel, transport it through endothelial cells, and concentrate it in tumor areas.

Paclitaxel (PTX) is a crucial chemotherapy drug used in cancer treatment. It works by binding to ?²-tubulin and causing microtubule overstabilization, which ultimately prevents mitosis.

In order to create more efficient paclitaxel derivatives, it is crucial to thoroughly understand the binding interactions between the drug and tubulin. Parness and Horwitz (1981) have shown that paclitaxel binds to the ?²-subunit of tubulin in a 1 : 1 stoichiometry. Rational drug design can then be employed based on this detailed understanding.

The unbound proportion of highly protein-bound drugs will increase in patients with hypoalbuminaemia due to a decrease in available binding sites.

Taxol, also known by its generic name paclitaxel, is a drug that stabilizes microtubules. It has been approved by the Food and Drug Administration for the treatment of ovarian, breast, and lung cancer, as well as Kaposi’s sarcoma.

The antitumor drug Taxol works by stabilizing microtubules and decreasing their movement, leading to the arrest of cell division and ultimately cell death. This is achieved by the drug’s ability to promote the assembly of the ?±/?²-tubulin heterodimer, which results in the hydrolysis of GTP bound to ?²-tubulin to GDP. This process establishes a balance between free tubulin dimers and microtubules.

Nab-paclitaxel is a colloidal suspension of paclitaxel and human serum albumin that utilizes the transport properties of albumin, without the need for a solvent.

Dose Level:
– Full dose: Paclitaxel protein-bound particles for injectable suspension (albumin-bound) – 125 mg/m2, Gemcitabine – 1000 mg/m2
– 1st dose reduction: Paclitaxel protein-bound particles for injectable suspension (albumin-bound) – 100 mg/m2, Gemcitabine – 800 mg/m2
– 2nd dose reduction: Paclitaxel protein-bound particles for injectable suspension (albumin-bound) – 75 mg/m2, Gemcitabine – 600 mg/m2
– If additional dose reduction required: Discontinue treatment
– If additional dose reduction required after 2nd dose reduction: Discontinue treatment

Paclitaxel affects longitudinal tubulin contacts along protofilaments in microtubules. This is believed to occur through the allosteric expansion of the microtubule lattice in the direction of its long filament axis (Vale et al., 1994; Arnal and Wade, 1995; Alushin et al., 2014).

Nab-paclitaxel is a solvent-free colloidal suspension consisting of particles measuring 130 nanometers. It is homogenized with human serum albumin at a concentration of 3%-4%. This formulation allows for the administration of higher doses of the drug compared to standard paclitaxel therapy, while minimizing side effects. Additionally, the infusion time is reduced to just 30 minutes and there is no need for a solvent.

Despite being initially developed to reduce the toxic effects of taxane treatment, nab-paclitaxel has shown to be more effective than conventional solvent-based paclitaxel in treating metastatic breast cancer, as demonstrated in several early clinical trials.

Albumin interacts with both endogenous ligands, such as fatty acids, and exogenous ligands, including warfarin, penicillin, and diazepam.

Information on Abraxane (paclitaxel protein bound) dosage, uses, potential drug interactions, side effects, and additional details.

A 90 ml_ sample of a 20% w/v HSA solution was mixed with water to make a total volume of 100 ml_. In a separate container, 2 g of Paclitaxel was dissolved in 6.75 ml_ of chloroform and 0.65 ml_ of ethanol. This Paclitaxel solution was then added to the diluted albumin solution described above.

Abraxane®, also referred to as nab-paclitaxel, is a medication utilized in the treatment of breast cancer, non-small cell lung cancer, and pancreatic cancer.

The Indian regulatory authority has approved Nanoxel, a nanoparticle formulation of the taxane, as a solution to the poor solubility of Paclitaxel (Taxol) in water. This alternative eliminates the need for cremophor as a solvent, which often leads to infusion reactions.

The binding of albumin to gp60 and SPARC enables the albumin-based nanoparticles to enhance their uptake. This mechanism enables the nanoparticles to evade the drug efflux mechanisms in tumor cells.

Paclitaxel, protein bound, is a type of chemotherapy treatment that involves binding paclitaxel particles with a protein called albumin, which is sourced from human blood. This method helps prevent the adverse reactions typically associated with the preservative used in regular paclitaxel and enables the administration of higher doses.

Paclitaxel protein-bound injection is administered as a treatment for metastatic breast cancer when other treatment options have been ineffective.

The price of a 100 mg supply of paclitaxel protein-bound intravenous powder for injection is approximately $1,460, varying depending on the pharmacy you choose.

Nab-paclitaxel, also known as Abraxane, is a chemotherapy drug that combines paclitaxel with the protein albumin.

Information on Abraxane (paclitaxel protein bound) dosage, uses, potential drug interactions, side effects, and additional details.

The nanoparticles are composed mainly of human albumin, with the majority of paclitaxel bound to it.

Abraxane, also known as albumin-bound or nab-paclitaxel, is a type of chemotherapy drug. It belongs to the class of Taxane chemotherapy, along with Taxol and Taxotere. The main mechanism of action of taxanes is to disrupt the division process of cancer cells.

However, although paclitaxel has significant effects on mitosis that can lead to cell death, it has been proposed that its mechanism of tumor death is through its effects on interphase cells.

After 24 hours of infusion, cisplatin has a protein-binding rate (PBR) of 98%, and the binding of platinum to protein is essentially permanent. The total and ultrafilterable platinum are eliminated quickly in two phases, primarily through the renal pathway.

There is currently no known remedy for overdosing on Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound).

Symptoms of an allergic reaction may include skin rash, itching, hives, swelling of the face, lips, or tongue, breathing difficulties, changes in vision, fast or irregular heartbeat, low blood pressure, mouth sores, and pain, tingling, or numbness in the hands or feet.

Hyaluronidase has been utilized in the management of extravasations caused by vinca alkaloids and taxanes. The recommended dosage of hyaluronidase is between 150 and 1,500 units, diluted in 1 mL of normal saline, and administered subcutaneously or intradermally within 1 hour of the extravasation event.

If you experience a cough, dizziness, wheezing, difficulty breathing, tightness in your chest or throat, swelling in your face or hands, fever, chills, rash, itching or hives, skin redness, or lightheadedness or faintness while taking this medication, inform your doctor or nurse immediately.

To prevent injury, it is recommended to refrain from participating in contact sports or activities that may lead to harm. Paclitaxel typically does not cause much nausea. However, if you do experience nausea, it is advised to take the anti-nausea medications prescribed by your doctor and consume small, frequent meals. Additionally, sucking on lozenges and chewing gum may provide relief.

There is currently no known remedy for paclitaxel overdosage. The main expected issues resulting from an overdose would include bone marrow suppression, peripheral neurotoxicity, and mucositis. In the case of pediatric patients, overdoses may also lead to acute ethanol toxicity (refer to the Pediatric Use section in the precautions).

Tumor cells are effectively eliminated by paclitaxel at clinically relevant concentrations through the induction of multipolar divisions. When exposed to paclitaxel concentrations similar to those found in human breast tumors, cells undergoing mitosis exhibit abnormal spindles with extra spindle poles.